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Accepted 19 July 2016Hypercholesterolemia and elevated homocysteine concentrations are associated with
cardiovascular risk. Previous studies have demonstrated a cholesterol-lowering effect of
red yeast rice (RYR) supplements which contained 5 to 10 mg of monacolin K. We
hypothesized that the intake of a low monacolin K dose may likewise reduce low-density
lipoprotein–cholesterol (LDL-C) and other plasma lipids. In secondary analyses, we tested
the homocysteine lowering effect of folic acid, which was also included in the study
preparation. Therefore, we conducted a randomized, double-blind, and placebo-controlled
intervention study. One hundred forty-two nonstatin-treated participants with hypercho-
lesterolemia (LDL-C ≥ 4.14 ≤ 5.69 mmol/L) were randomized to the supplement group with
RYR or the placebo group. Participants of the supplement group consumed 3 mg monacolin
K and 200 μg folic acid per day. A significant (P < .001) reduction of LDL-C (−14.8%), total
cholesterol (−11.2%), and homocysteine (−12.5%) was determined in the supplement
group after 12 weeks. A total of 51% of the participants treated with RYR achieved the
limit of LDL-C <4.14 mmol/L advised and 26% reached the threshold level of
homocysteine <10 μmol/L. No significant changes were exhibited within the placebo
group. Other parameters remained unchanged and no intolerances or serious adverse
events were observed. In conclusion, we demonstrated that a low dose of daily 3 mg
monacolin K from RYR reduces the concentration of LDL-C; a risk factor for cardiovascular
diseases.
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Hypercholesterolemia is a well-known risk factor for cardio-
vascular diseases (CVD) and coronary heart diseases [1,2].
Epidemiological studies have shown a direct correlation
between low-density lipoprotein–cholesterol (LDL-C) and the
risk of atherosclerosis and myocardial infarction [3]. Reducing
total cholesterol (TC) and LDL-C plasma levels are an
established and effective strategy in the prevention of
coronary events [4,5]. Several meta-analyses indicate that a
LDL-C reduction of 1 mmol/L is associated with a 20% to 23%
reduction in coronary and vascular disease risks [6,7].
Providing that no other risk factors exist, LDL-C levels
of ≥4.14 mmol/L are considered borderline high and should
be lowered [3]. Changes in lifestyle, especially dietary modi-
fication (increased consumption of unsaturated fatty acids
and dietary fibers), and regular physical activities are the
primary treatment approach. If other risk factors, such as
hypertension, dyslipidemia, or atheroscleroticvascular diseases,
exist, a drug treatment with statins or bile acid sequestrant
could be necessary. In the case of hypercholesterolemia,
balanced diets constitute the main nutritive strategy for
lowering blood lipids. Furthermore, enriched food and food
supplements (ie, containing phytosterols) are discussed as an
additional measure [8-10].
Red yeast rice (RYR) is a traditional food in many Asian
countries and a favored ingredient for the preparation of fish,
meat, or even rice wine [11]. It has been used to promote
digestion as well as blood circulation ever since the Ming
Dynasty [12]. Red yeast rice is produced by the fermentation
of white rice and the mold fungus Monascus purpureus. Red
dyestuffs, flavors, and especially components such as
monacolins occur according to the fermentation conditions
[12]. Monacolins—in particular monacolin K, which has an
identical structure to lovastatin [13]—inhibit the activity of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
As a result, the endogenous synthesis of cholesterol is
reduced and elevated cholesterol levels decrease. Several
intervention studies demonstrated that RYR containing 5 to
10 mgmonacolin K lowers elevated LDL-C levels by about 22%
to 27% [14-18]. The European Food Safety Authority considers
that a daily intake of 10mgmonacolin K from RYR contributes
to the maintenance of a normal LDL-C plasma level [19].
However, studies in which participants supplemented RYR
products with a low dosage of 3 mg monacolin K plus other
cholesterol-lowering agents, such as berberine or policosanols,
observed a decrease of the LDL-C level by 20% to 31% [20-24].
However, the supplements used contained additional cholesterol-
lowering agents and, because of this combination, it is difficult to
determine whether the lipid-lowering effect was achieved mainly
bymonacolin K or another agent.
In addition to hypercholesterolemia, elevated levels of
homocysteine are associated with a high risk of CVD, stroke,
and venous thrombosis [25-27]. Decreasing homocysteine
levels might be effective in the prevention of CVD [28,29],
although several studies failed to show this relationship [30-32].
Homocysteine is a nonessential amino acid, which is converted
into methionine or metabolized to cysteine by using the
cofactors folic acid and vitamin B12 or B6. Deficits in thesevitamins inhibit the degradation and induce an increase of
homocysteine (hyperhomocysteinemia). Several studies have
shown that elevated homocysteine concentrations could be
reduced through a supplementation of folic acid in doses of 0.1
to 10.0 mg [33-35].
Previous intervention studiesdemonstrated anLDL-C-lowering
effect of RYR in doses ranged from 5 to 10 mg/d monacolin K
[36,37]. In thepresent study, theefficacyof a combinedpreparation
with a low dose of monacolin K (3 mg/d) together with a
physiological dose of folic acid (200 μg/d) was investigated. We
hypothesized a LDL-C lowering-effect in hypercholesterolemic
participants after intake of 3 mg/d monacolin K from RYR
extract. To test this hypothesis, we conducted a randomized,
double-blind, and placebo-controlled intervention study. Our
main objective was to determine the plasma level especially of
LDL-C at baseline, after 6 and 12weeks of treatment. Secondary
objectivewas to analyze thehomocysteine-lowering effect after
intake of 200 μg/d folic acid.2. Methods and materials
The randomized, placebo-controlled, and double-blind inter-
vention study was planned and conducted according to the
set of ethical principles laid down in the Declaration of
Helsinki, which was revised for the most recent time in 2013,
and to the guidelines of Good Clinical Practice. The study
protocol was approved by the Ethical Committee of the
Medical Chamber of Lower Saxony (Hannover). The interven-
tion study was registered in the German Clinical Trials
Register (identification no. DRKS00006189). The examinations
for the nutritional study were carried out from July 2014 to May
2015 at the Institute of Food Science and Human Nutrition,
Leibniz University of Hannover, Germany and at the TRIAMEDIS
health center, a facility of Hospital Nordwest, Department of
Gynecology and Obstetrics, Frankfurt amMain, Germany.
2.1. Participants
Male or female participants were recruited by advertisement
in daily and weekly newspapers in the greater area of
Hannover and Frankfurt am Main. Inclusion criteria were an
LDL-C level ≥4.14 mmol/L and ≤5.69 mmol/L and an age
between 18 and 70 years. Exclusion criteria were defined as
follows: body mass index (BMI), >35 kg/m2; triacylglycerol (TG)
level, ≥4.52 mmol/L; chronic diseases (eg, malignant tumors,
manifest CVD, insulin-dependent type 1 and 2 diabetes,
severe renal, or liver diseases); chronic gastrointestinal
disorders (especially small intestine, pancreas, and liver) and
prior gastrointestinal surgical procedures (eg, gastrectomy,
coeliac disease, enterocolitis, chronic pancreatitis, cholesta-
sis, short bowel syndrome, chronic inflammatory bowel
disease); hormonal disorders (eg, Cushing's syndrome and
untreated hyperthyroidism); uncontrolled hypertension; in-
take of lipid lowering drugs (including statins, fibrates, bile
acid binders, nicotinic acid, and Ezetimibe) or supplements
(including ω-3 and -6 fatty acids, β-glucans, betaine, ketosan,
glucomannan, guar resins, hydropropyl methylcellulose, RYR
products, oleic acid, pectins, plant sterols/stanols, and their
Table 1 – Chemical composition of the RYR preparation
and placebo
Ingredients RYR preparation
(mg/tablet)
Placebo
(mg/tablet)
Dicalcium phosphate 304.6 –
Dibasic calcium phosphate – 499.0
Microcrystalline cellulose 253.2 318.3
Monacolin K 3.0 –
Astaxanthin 0.5 –
Magnesium stearate 8.0 8.3
Mono- and diglycerides of fatty
acids
8.0 –
Silicon dioxide 4.0 4.1
Coenzym Q10 2.0 –
Pteroyl monoglutamic acid
(folic acid)
0.2 –
Red iron oxides – 8.3
Brown iron oxides – 2.1
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dosage of the following medications: (oral) corticosteroids,
contraceptives, hormone replacement therapy, thiazide di-
uretics, β-blockers, antidiabetics; myopathy and unexplained
muscle pain; pregnancy and breastfeeding; and addiction to
alcohol, drugs, and/or medications. All participants gave their
written informed consent before the first examination.
2.2. Study design
The study consisted of a screening phase and a 12-week long
intervention period with 3 examinations: baseline examina-
tion (t0), intermediate examination after 6 weeks (t6), and final
examination after 12 weeks (t12). Interested participants were
informed, filled in an admission questionnaire, and had to
show a laboratory result with the current cholesterol levels
(not older than 1 year). Potential participants who met the
inclusion criteria without showing exclusion criteria were
invited to t0. On the basis of the blood values of t0 (especially
LDL-C and TG), suitable participants were included in the
study, 1 day after t0. All participants received investigational
products by post and were informed about the start of
intervention (1 week after t0). Participants ingested either
the preparation with RYR or the placebo during the 12-week
study. The daily intake of 1 tablet should occur every evening
at dinner time with an adequate amount of liquid (eg, water).
Anthropometric data (height, body weight, waist and hip
circumferences, blood pressure, heart rate) were measured at
t0, t6, and t12. Participants filled in questionnaires to check the
current state of health, medications, physical activity, and the
presence of any side effects.
The RYR preparation contained per tablet was 200.0 mg
RYR (3.0 mg monacolin K), 2.0 mg coenzyme Q10, 0.5 mg
astaxanthin, and 200.0 μg folic acid (Armolipid by Madaus
GmbH Köln, Germany—now a part of MEDA Pharma, Bad
Homburg, Germany). The RYR preparation was free of
citrinin—a nephrotoxic and hepatotoxic mycotoxin which
could occur as a by-product due to the fermentation process
of RYR [38]. The placebo was similar in appearance and flavor,
but without any effective ingredients (Table 1). All partici-
pants were randomly assigned in a 1:1 ratio into 2 treatment
groups: supplement group (s-group) and placebo group (p-
group). Participants were stratified by sex and LDL-C concen-
tration and, therefore, 2 ranges of LDL-C concentrations were
determined: low range (4.14-4.89 mmol/L) and high range
(4.91-5.69 mmol/L). The investigational products (RYR prepa-
ration and placebo) were randomized in a 6-block system by a
noninvolved third party. All participants, investigators, phy-
sicians, and all the study team members were blinded to
treatment allocation throughout the 12-week study. Evalua-
tion of the compliance occurred through counting all tablets
returned and comparing the results with the intake recom-
mended. A regular consumption was expected when the
quantity of forgotten tablets did not exceed 10%. Participants
were classified as compliant if they visited t0 and 1 further
examination, and if they consumed the investigational
products regularly. All participants were asked to maintain
their usual eating patterns and physical activity during the
intervention. Participants had to fill in a 3-day dietary record
(1 weekend day and 2 weekdays) at the beginning and end ofthe study. Nutrition calculations were carried out using PRODI
(Nutri-Science GmbH, Freiburg, Germany).
The primary end point of the present intervention study was
to observe the reduction of LDL-C in the s-group compared with
the p-group over the study duration of 12 weeks. Secondary end
points were the determination of the effects on homocysteine
and other plasma lipids (TC, high-density lipoprotein–cholesterol
[HDL-C], TG), as well as safety parameters and parameters such
as fasting glycaemia or high sensitive C-reactive protein.
2.3. Plasma collection and analyses
Venous blood samples were gathered in the morning at t0, t6,
and t12 after an overnight fasting for 12 hours. In total, 50 mL
bloodwas taken from each participant by a qualified physician.
The blood samples were stored at +4°C until analyses, which
were conducted by an external laboratory (LADR, Hannover,
Germany). Plasma lipids (TC, LDL-C, HDL-C, LDL-C/HDL-C ratio,
TG) were measured by using an enzymatic colorimetric assay.
Homocysteine levels were determined by high-performance
liquid chromatography. Creatinine was measured using a
kinetic colorimetric assay. Fasting blood glucose was deter-
mined by an enzymatic UV method (hexokinase method) and
fasting insulinwasmeasured by an immunological in vitro test.
2.4. Statistical analyses
Normal distribution of the whole data set was analyzed by
using the Kolmogorov-Smirnov test. The unpaired t test was
used for normal distributed data to compare the 2 treatment
groups and the paired t test was used to compare within
group differences from t0. Intragroup and intergroup differ-
ences of skewed distributed data were analyzed by using the
Mann-Whitney U test and Wilcoxon test. The comparison
between the treatment groups for categorical variables was
performed using the χ2 test. Expecting a 15% dropout rate, a
sample size of 80 participants per group (s- and p-group)
would provide 80% power to detect a significant difference
between the treatment groups. Differences were considered
Table 2 – Anthropometric and biochemical characteristics
of the study participants at baseline (t0)
Total
group
S-group P-group P value
Number
of participants
142 70 72
Sex distribution (m/f) 53:89 27:43 26:46 .762#
Age (y) 57.3 ± 7.0 57.5 ± 7.2 57.0 ± 6.8 .645†
Weight (kg) 77.5 ± 15.4 78.4 ± 16.2 76.6 ± 14.7 .570†
1165N U T R I T I O N R E S E A R C H 3 6 ( 2 0 1 6 ) 1 1 6 2 – 1 1 7 0significant at a P value ≤.05. Results were presented as mean
values ± standard deviation (SD). Moreover, difference between
time points was indicated in percentage.
All statistical analyses were carried out in the intention-to-
treat population. In case of withdrawal or absence during t6 or
t12, the missing values were substituted by the principle of
the last observation carried forward. Statistical Package of Social
Sciences 21.0 (SPSS Inc, Chicago, Illionois, USA) was used for the
statistical analysis of anthropometric and laboratory chemical data.Height (m) 1.71 ± 0.10 1.70 ± 0.09 1.72 ± 0.10 .296‡
BMI (kg/m2) 26.4 ± 4.1 26.9 ± 4.2 25.9 ± 3.9 .163†
WC (cm) 90.9 ± 12.4 92.3 ± 12.7 89.5 ± 12.1 .247†
HipC (cm) 103.0 ± 9.3 103.6 ± 9.4 102.4 ± 9.1 .469†
SBP (mm Hg) 130.7 ± 17.2 131.2 ± 17.2 130.3 ± 17.3 .643‡
DBP (mm Hg) 79.5 ± 10.3 78.7 ± 8.4 80.3 ± 11.9 .443‡
Heart rate (bpm) 68.0 ± 8.1 67.9 ± 9.0 68.1 ± 7.1 .960‡
LDL-C (mmol/L) 4.88 ± 0.43 4.86 ± 0.41 4.91 ± 0.44 .433‡
Values are shown as means ± SD; s-group, supplement-group; p-group,
placebo-group; m, male participants; f, female participants; BMI, body
mass index; WC, waist circumference; HipC, hip circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; LDL-C, LDL-
cholesterol; # χ2 test; † t test; ‡Mann-Whitney U test.3. Results
3.1. Study population
Atotal of 235participantswere invited to thebaseline visit (Fig. 1).
One hundred fifty-one participants fulfilled the inclusion and
exclusion criteria, were included in the study, and were
randomized to the s-group (n = 73) or p-group (n = 78).
Nine participants (6.0%) dropped out after t0 and did not visit
the intermediate examination. Thus, 142 men and women were
involved in the intention-to-treat analysis. All participants were
consistently divided between the 2 treatment groups: s-group
(n = 70, 27 males, 43 females) and p-group (n = 72, 26 males, 46
females). In total, more female than male participants were
included in the study population; however, the relation between
male and female was similar between the 2 groups.
No differences were observed among the treatment
groups at t0 regarding parameters such as sex, age, BMI, hip
andwaist circumferences, bloodpressure, heart rate, and LDL-C
levels (Table 2). The analysis of the 3-day dietary records
showednodifferences between the s-groupand p-group at t0 as
well as at the end of the intervention study (data not shown).
3.2. Parameters of lipid metabolism
The mean LDL-C levels of both treatment groups at t0 were
within the range targeted of ≥4.14 mmol/L and ≤5.69 mmol/L
(s-group, 4.86 mmol/L; p-group, 4.91 mmol/L), which is consid-
ered as borderline-high. The LDL-C levels did not differ betweenAssessed for e
(n = 235
Randomiza
(n = 151
S-group (n = 73)
Intention-To-Treat-Population:
Analyzed data (n = 70) 
in s-group 
Drop out 
(n = 3)
Fig. 1 – Flow diagram of the study populatithe s-group and p-group at the beginning of the study (P = .433;
Fig. 2). TheLDL-Cconcentrationdecreased significantly (−14.8%;P
< .001) in the s-groupafter 12weeks (primary endpoint). TheLDL-
C concentrationof the s-groupwassignificantly (P< .001) reduced
by 14.9% after 6 weeks and reached a level of 4.13 mmol/L at t6,
which was constant until the end of the study (Fig. 2). A total of
53% of the participants in the s-group reached the LDL-C
threshold level of <4.14mmol/L [3] after 6weeks of intervention
(t6) and 51% achieved this level after 12weeks of treatment (t12).
The LDL-C levels in the p-group were reduced by 2.7% at t12;
however, the change was not significant. In comparison with
the p-group, the LDL-C concentrations of the s-group were
significantly (P < .001) different at t6 and t12.
The levels of further plasma lipids, such as TC, HDL-C,
and LDL-C/HDL-C ratio, did not differ between the s-group
and p-group at the beginning of study (Table 3). The TG level
of the s-group was 7.0% higher than in the p-group at t0,
whereby this difference was not significant. The lowered LDL-Cligibility
) Excluded (n = 84)
• Not meeting inclusion/ 
exclusion criteria
(esp. blood lipid levels)tion
)  
P-group (n = 78) 
Drop out 
(n = 6)
Intention-To-Treat-Population:
Analyzed data (n = 72) 
in p-group 
on. n indicates number of participants.
Fig. 2 – Low-density lipoprotein-cholesterol concentration at
baseline (t0), after 6 (t6) and 12 (t12) weeks of intervention. Values
are shown asmeans ± SD; s-group, supplement-group; p-group,
placebo-group; LDL-C, LDL-cholesterol; † t test for unpaired data;
‡Mann-Whitney U test; ** Wilcoxon test.
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tion and LDL-C/HDL-C ratio in the s-group. The TC levels in the
s-group decreased significantly by 11.2% and the LDL-C/HDL-C
ratio was lowered by −14.1% (Table 3). These differences
occurred mainly in the first 6 weeks of intervention and both
parameters at least reached a constant level during the period
between t6 and t12. No significant differences in TC (−1.0%; P =
.515) and LDL-C/HDL-C ratio (−2.2%; P = .116) were observed
within the p-group during the whole intervention period.
Furthermore, HDL-C levels remained unchanged in the s-group
andp-group throughout the entire durationof the study (Table 3).
The level of TG was reduced by 5.0% in the s-group from t0 to t12
(P = .001). However, differences between the TG concentrations of
the s-group and p-group were not significant at any time point.
Participants of the s-group were separated into a subgroup
with slightly elevated LDL-C levels (4.14-4.89 mmol/L) and
compared with a subgroup with high LDL-C levels (4.91-5.96
mmol/L) at baseline t0 (Table 4). The LDL-C-lowering was
stronger in s-group participants with higher LDL-C levelsTable 3 – Serum lipid concentrations at baseline (t0), after 6 (t6)
Lipid parameter Treatment groups t0
TC (mmol/L) S-group (n = 70) 7.00 ± 0.65
P-group (n = 72) 6.97 ± 0.67
P value (s-group vs p-group) .833‡
HDL-C (mmol/L) S-group (n = 70) 1.64 ± 0.42
P-group (n = 72) 1.59 ± 0.36
P value (s-group vs p-group) .583‡
LDL-C/HDL-C ratio S-group (n = 70) 3.1 ± 0.8
P-group (n = 72) 3.3 ± 0.8
P value (s-group vs p-group) .409‡
TG (mmol/L) S-group (n = 70) 1.59 ± 0.78
P-group (n = 72) 1.47 ± 0.63
P value (s-group vs p-group) .487‡
Values are shown as means ± SD; s-group, supplement-group; p-group, p
HDL-cholesterol; LDL-C, LDL-cholesterol; TG, triacylglycerides; %, percent
.001 analyzed by Wilcoxon test.(17.1%) compared with slightly elevated LDL-C levels at t0,
where the relative LDL-C reduction was 12.8%.
3.3. Homocysteine
The levels of homocysteine were similarly elevated in both
treatment groups at t0 (P = .797) and were above the normal
plasma homocysteine level of <10 μmol/L (Table 5). The
homocysteine concentrations of the s-group were significantly
reduced by 12.5% and reached a mean of 10.2 μmol/L at t12.
The homocysteine level at the beginning of the study (t0)
was >10 μmol/L in 76% of the participants in the s-group,
whereas 50% of the participants reached the threshold level
of <10 μmol/L at t12. Thus, the homocysteine concentration of
26% of the s-group participants was lowered and reached the
reference range. No changes of the homocysteine values were
observedwithin thep-groupduring thewhole interventionperiod.
3.4. Safety parameters, adverse events, and compliance
All safety parameters (creatinine, creatine kinase, uric acid,
aspartate aminotransferase, alanine aminotransferase,
gamma-glutamyl transferase) analyzed as well as fasting
glucose, fasting insulin, HbA1c, and high sensitive C-reactive
protein showed neither undesirable changes in response to
RYR treatment nor significant differences between the 2
treatment groups at any time point. All values were within
the reference ranges throughout the whole study duration.
No serious adverse events were observed during the
intervention period of 12 weeks. Flatulence was the most
common adverse event in the s-group and p-group (1% of the
whole study population), which occurredwith similar frequency
in both treatment groups. Diarrhea, obstipation, and abdominal
fullness occurred seldom and in the s-group as frequently as in
the p-group. Belching was more common in the s-group at t12
(with a difference of 6%).
Three of the 9 dropouts received the preparationwith RYR and
6, the placebo. Participantswho took the RYRpreparation droppedand 12 (t12) weeks of intervention
t6 t12 t12-t0
Difference % Difference
6.25 ± 0.73** 6.20 ± 0.74** −0.80 ± 0.66 −11.2 ± 9.2
6.88 ± 0.88 6.88 ± 0.90 −0.09 ± 0.78 −1.0 ± 11.2
<.001‡ <.001†
1.64 ± 0.42 1.65 ± 0.44 0.01 ± 0.20 0.7 ± 12.3
1.57 ± 0.41 1.60 ± 0.40 0.00 ± 0.18 0.2 ± 11.3
.394‡ .438†
2.7 ± 0.8** 2.7 ± 0.9** −0.4 ± 0.4 −14.1 ± 13.5
3.2 ± 0.9 3.2 ± 0.9 −0.1 ± 0.4 −2.2 ± 12.6
<.001‡ .001‡
1.43 ± 0.67* 1.49 ± 0.93* −0.10 ± 0.69 −5.0 ± 40.6
1.55 ± 0.67 1.42 ± 0.66 −0.05 ± 0.49 −0.4 ± 28.4
.150‡ .700‡
lacebo-group; n, number of participants; TC, total cholesterol; HDL-C,
age of difference; † t test; ‡ Mann-Whitney U test; * P < .01 and ** P <
Table 4 – Changes in lower and higher LDL-C subgroups of the supplement group at baseline (t0) and after 12 (t12) weeks of
intervention
s-group t0 (mmol/L) t12 (mmol/L) Difference t12-t0
(mmol/L) %
Lower LDL-C group: 4.14-4.89 mmol/L (n = 38) 4.54 ± 0.22 3.95 ± 0.53** −0.58 ± 0.50 −12.8 ± 11.2
Higher LDL-C group: 4.91-5.69 mmol/L (n = 32) 5.24 ± 0.21 4.34 ± 0.54** −0.89 ± 0.50 −17.1 ± 9.5
Values are shown as means ± SD; s-group, supplement-group; n, number of participants; LDL-C, LDL-cholesterol; %, percentage of difference; **
P < .001 analyzed by Wilcoxon test.
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restless sleep as reasons. Participants of the p-group gave the
following reasons for interrupting the intervention: restless sleep,
stomach problems, joint and muscle pain, exhaustion, fatigue,
and operation/influenza (independent of the study).
A total of 90.8% (n = 129) of the participants were compliant
and 9.2% (n = 13) were not compliant.4. Discussion
Previous studies with RYR and the daily monacolin K dosages
between 5 and 10 mg proved an LDL-C-lowering effect in the
range of 20% to 30% [37,39-43]. In the present study,we show that
the RYR extract tested in a daily dose of only 3 mg monacolin K
led to a significant cholesterol-lowering effect. The LDL-C level
was reduced by about 15% in the s-group compared with the p-
group during the whole study duration. Themean LDL-C level in
the s-group dropped under the National Cholesterol Education
Program limit advised of <4.14 mmol/L [3] after 6 and 12 weeks
(4.13 mmol/L at each time point) of RYR treatment. More than
half of the participants supplemented with RYR reached that
National Cholesterol Education Program treatment goal, most of
them after a treatment of 6 weeks. Together, these data show
that borderline high LDL-C levels from nonstatin-treated partic-
ipants can be effectively lowered despite the low dosage of 3 mg
monacolin K in the RYR extract used.
Most studies with a total intervention time of 8 or 12 weeks
showed a considerable LDL-C-lowering effect of RYR supple-
mentation after 4 or 8 weeks of treatment [14,15,17]. A
constant level of LDL-C is probably reached rapidly after a
few weeks and remains consistent until the end of the study.
The inhibiting effect on HMG-CoA reductase might occur dueTable 5 – Homocysteine at baseline (t0) and after 12 (t12)
weeks of intervention
Treatment
groups
t0
(μmol/L)
t12
(μmol/L)
Difference t12-t0
(μmol/L) %
s-group (n = 70) 12.0 ± 4.2 10.2 ± 2.3** −1.9 ± 3.2 −12.5 ± 14.6
p-group (n = 72) 11.7 ± 2.6 11.6 ± 3.3 −0.1 ± 2.4 −0.4 ± 20.6
P value
(s- vs p-group)
.797‡ .002‡
Values are shown as means ± SD; s-group, supplement-group; p-group,
placebo-group; n, number of participants; %, percentage of difference; ‡
Mann-Whitney U test; ** P < .001 analyzed byWilcoxon test.to a saturated mechanism. Monacolin K inhibits the activity
of HMG-CoA reductase and the endogenous cholesterol
synthesis is impaired [44]. Because less endogenous choles-
terol is produced, the cholesterol level decreases slowly and a
constant level is reached after a few weeks and remains
consistent. Further studies including tight measurement time
points are required to investigate the time point of the
maximal reduction and LDL-C steady state with a certain
monacolin K dose from RYR. It should be noted that the LDL-
C-reducing effect of monacolin K from RYR could be depen-
dent on the dose administered and on the basal LDL-C levels.
Heber et al (1999), for example, demonstrated that a daily
intake of 7.5 mg monacolin K lowered the LDL-C levels by 22%
after a treatment of 12 weeks [14]. In our study, we proved a
LDL-C reduction of about 15% in response to a supplementa-
tion of 3 mg monacolin K within 12 weeks. The basal LDL-C
concentrations of both intervention studies were ≥4.14 mmol/L.
Moreover, we observed in the present study a greater LDL-C
reduction in participants with higher basal LDL-C concentrations
(4.91-5.69mmol/L) compared with participants with lower LDL-C
levels (4.14-4.89 mmol/L) in response to RYR intake. Further
studies includingdifferent dosesofmonacolinKanda separation
of the participants in subgroupswith different basal LDL-C levels
are required to investigate the cholesterol-lowering effect.
Equally, the opposite question arises whether the LDL-C
reduction maintains over a long-term period. A trial with a daily
intake of 10.0 to 12.8mgmonacolin K suggested a constant LDL-C
reduction of 20% over a period of 4.5 years [16]. However, further
long-term studies are necessary to confirm these results and to
evaluate the long-term tolerability of RYR supplements with low
and high monacolin K doses from RYR extracts. No intolerances
or serious adverse events were observed during the intervention
with a low dosage of monacolin K (3 mg/d) in the present study.
It is difficult to compare intervention studies with RYR
extracts, because most studies only indicate the RYR dosage
without giving information on the daily monacolin K dose.
However, monacolin K is the key agent in RYR extract to lower
cholesterol levels by inhibiting the activity of HMG-CoA
reductase, resulting in an inhibition of the endogenous
cholesterol synthesis [44]. Thus, the monacolin K dose is
required to interpret the efficacy of RYR extracts among
studies. Furthermore, the concentration of monacolin K can
vary in supplements with a similar amount of RYR. Heber et al
(2001) investigated 9 Chinese supplements containing RYR
and found that the monacolin K content ranged from 0.15 to
3.37 mg/capsule [38]. It is recommended that further studies
with RYR extract indicate the monacolin K dose clearly.
Because of the fermentation process, RYR contains addi-
tional bioactive compounds. In addition to monacolin K, these
1168 N U T R I T I O N R E S E A R C H 3 6 ( 2 0 1 6 ) 1 1 6 2 – 1 1 7 0include 13 other monacolins as well as their hydroxy acid
forms, fiber, unsaturated fatty acids, plant sterols, isoflavones,
and isoflavone glycosides [11,12,45]. Compounds such as fiber
and plant sterols contribute to the cholesterol-lowering effect
[46,47] and may act synergistically in the RYR [11,41,48].
Monacolin K is considered as the most effective among all
compounds in the reduction of cholesterol levels.
An effect of coenzyme Q10 on the cholesterol metabo-
lism was observed in the murine model [49,50]. However,
several human intervention studies demonstrated no
beneficial effects on LDL-C levels or other lipid parameters
after supplementing doses of 200 mg/d coenzyme Q10 over
3 to 6 months [51-53]. In our study, the coenzyme Q10 dose
was 100-fold lower (2.0 mg/d). Hence, a cholesterol-
lowering effect of coenzyme Q10 is unlikely.
The homocysteine-lowering effect of folic acid has been shown
in various studies in concentrations of −3.0 to −4.4 μmol/L; however,
it ranged from 2.5 to 10.0 mg folic acid per day in pharmacological
doses [33,54,55]. In the present study, we observed a significant
homocysteine-lowering effect (−12.5%) after an intervention of 12
weekswith a physiological folic acid concentration (200 μg a day). A
total of 26% of the participants from the s-group reached the
reference value of <10 μmol/L recommended, whereas no changes
in the homocysteine concentrationwere observed in participants of
the p-group. Comparable intervention trials supplementing folic
acid in similar concentrations (200-250μg a day) to participantswith
similar basal homocysteine levels showed a homocysteine reduc-
tion of about 10% to 12% [35,56,57]. Thus the effect size in these
studies is comparable with our findings.
The study has a number of potential limitations. Potential
antioxidant effects of astaxanthin and coenzyme Q10 (eg, on
oxidized LDL-C), which were also included in the study prepara-
tion, were not evaluated. However, because of the low dosage of
coenzyme Q10 and astaxanthin, antioxidant effects are rather
not to be expected. Likewise, the endogenous levels of folic acid
were not analyzed, which would have been useful to elevate the
supply status of this B vitamin. The strengths of our study rely on
the high sample size, the relatively long duration and the
straightforward design. Similarly, our study yielded data on the
safety and tolerability of the RYR preparation used.
In conclusion, our study demonstrated that a relatively low
content of RYR (3 mg monacolin K per day) can reduce elevated
concentrations of LDL-C in nonstatin-treated participants significant-
ly. Thus, these results confirm our hypothesis. Furthermore, a
physiological dose of folic acid (200 μg per day) can lower elevated
homocysteine levels significantly. Hence, the study preparation used
is effective in lowering cholesterol and homocysteine and may be
practically integrated in a primary CVD and coronary heart diseases
prevention strategy.Acknowledgment
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